Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Sundar Jagannath
October 24, 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
8th Annual Houston Methodist Cancer Symposium

8th Annual Houston Methodist Cancer Symposium

Fri, Aug 7, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Aug 15, 2020
The Asian Oncology Society 1st International Conference

The Asian Oncology Society 1st International Conference

Sun, Aug 16, 2020
Total Health Conferencing

2020 ASCO Virtual Direct™ Highlights - San Juan

Fri, Aug 7, 2020
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering MM, I...

Feat. K. Shain
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
19:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Di...

Feat. R. Vij
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:44
Bart Barlogie

Clinical Manifestations & Diagnostic Work Up of Myeloma

19:49
Gareth J Morgan

Contemporary Design of MM Treatment: Developing New Therapeutic Endpoint...

17:03
Ajai Chari

Diagnosing Smoldering Multiple Myeloma

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
05:05
Indy Hematology Review

Risk of Progression of Smoldering Myeloma to Active Multiple Myeloma

Feat. K. Anderson
08:25
Cristina Gasparetto

2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...

15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin